Dimensional Fund Advisors
FHTX icon

Dimensional Fund Advisors’s Foghorn Therapeutics FHTX Stock Holding History

Dimensional Fund Advisors’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-19,758
Closed -$300K – 3486
2022
Q1 		$300K Buy
+19,758
New +$271K ﹤0.01% 3250

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Dimensional Fund Advisors's FHTX Position: Q2 2022 in Review

Dimensional Fund Advisors sold out of Foghorn Therapeutics (FHTX) in Q2 2022, closing a stake of 19,758 shares — an estimated $300K sold.

Dimensional Fund Advisors first reported a position in FHTX in Q1 2022 and held it in 1 quarter. The position peaked at $300K in Q1 2022. 60 funds tracked by Wall St. Rank hold FHTX as of Q2 2022.

  • Dimensional Fund Advisors reported no remaining Foghorn Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Dimensional Fund Advisors sold 19,758 Foghorn Therapeutics shares in Q2 2022, an estimated $300K.
  • Dimensional Fund Advisors first reported a position in Foghorn Therapeutics in Q1 2022 and held it in 1 quarter.
  • Dimensional Fund Advisors's Foghorn Therapeutics position peaked at $300K in Q1 2022.
  • 60 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2022.

Based on Dimensional Fund Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.